Unknown

Dataset Information

0

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.


ABSTRACT: Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies, and the incidence of RCC continues to rise worldwide. Although RCC can be treated with surgery at an early stages, the five-year survival rates have been observed to decline dramatically in patients with advanced disease. Most patients with RCC treated with cytotoxic or targeted drugs will develop resistance at some point during therapy. Thus, it is necessary to identify novel therapeutic targets for RCC. Here, we found that RANBP2-type and C3HC4-type zinc finger-containing 1 (RBCK1) expression was upregulated in human RCC samples. Analysis of multiple public databases revealed the correlation between RBCK1 expression and poor prognosis in RCC patients. Subsequently, we performed RBCK1 depletion experiments in RCC cells that severely affected the in vivo and in vitro proliferation of renal cancer cells. The effects of RBCK1 on cell proliferation could be rescued with p53 expression knockdown in two cell lines expressing wild-type p53. Further experiments demonstrated that RBCK1 could facilitate p53 poly-ubiquitination and degradation by direct interaction with p53. Together, our results show that RBCK1 may serve as a promising target for RCC therapy by restoring p53 functions.

SUBMITTER: Yu S 

PROVIDER: S-EPMC6420644 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.

Yu Sifan S   Dai Jie J   Ma Meng M   Xu Tianxiao T   Kong Yan Y   Cui Chuanliang C   Chi Zhihong Z   Si Lu L   Tang Huan H   Yang Lu L   Sheng Xinan X   Guo Jun J  

Cell death & disease 20190315 4


Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies, and the incidence of RCC continues to rise worldwide. Although RCC can be treated with surgery at an early stages, the five-year survival rates have been observed to decline dramatically in patients with advanced disease. Most patients with RCC treated with cytotoxic or targeted drugs will develop resistance at some point during therapy. Thus, it is necessary to identify novel therapeutic targets for RCC. Here, we fo  ...[more]

Similar Datasets

2019-03-28 | GSE119864 | GEO
| S-EPMC5355047 | biostudies-literature
| PRJNA490504 | ENA
| S-EPMC10244087 | biostudies-literature
| S-EPMC8204444 | biostudies-literature
| S-EPMC4891009 | biostudies-literature
| S-EPMC8684721 | biostudies-literature
| S-EPMC9307510 | biostudies-literature
| S-EPMC8500977 | biostudies-literature
| S-EPMC8486188 | biostudies-literature